Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 2/2016

01-02-2016 | Capsule Commentary

Capsule Commentary on Lafata et al., Medication Adherence Does Not Explain Black-White Differences in Cardiometabolic Risk Factor Control among Insured Patients with Diabetes

Author: Ana M. Palacio, MD, MPH

Published in: Journal of General Internal Medicine | Issue 2/2016

Login to get access

Excerpt

The study by Lafata et al. evaluated whether medication adherence mediated racial disparities in achieving HBA1c, LDL or SBP targets among diabetics.1 The authors found that blacks had poorer medication adherence compared to whites in all three classes of medications, and were less likely to achieve clinical targets. Racial disparities persisted in multivariable models that included medication adherence and treatment intensification. The strengths of the study are the inclusion of patients from multiple sites and the use of objective adherence and outcome data. A limitation was the use of an adherence definition that required having at least two prescriptions filled, since the exclusion of subjects with no or one refill could have introduced bias. …
Literature
1.
Lafata JE, Karter AJ, O’Connor PJ, Morris H, Schmittdiel JA, Ratliff S, Newton KM, Raebel MA, Pathak RD, Thomas A, Butler MG, Reynolds K, Waitzfelder B, Steiner JF. Medication adherence does not explain black-white differences in cardiometabolic risk factor control among insured patients with diabetes. J Gen Intern Med. doi:10.​1007/​s11606-015-3486-0.
2.
Collins SD, Torguson R, Gaglia MA Jr, et al. Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation. 2010;122(11):1085–90.CrossRefPubMed
3.
Kramer MR, Valderrama AL, Casper ML. Decomposing black-white disparities in heart disease mortality in the united states, 1973–2010: An age-period-cohort analysis. Am J Epidemiol. 2015.
4.
Chin MH, Clarke AR, Nocon RS, et al. A roadmap and best practices for organizations to reduce racial and ethnic disparities in health care. J Gen Intern Med. 2012;27(8):992–1000.PubMedCentralCrossRefPubMed
5.
Smedley B, Stith A, Nelson A. Unequal treatment confronting racial and ethnic disparities in health care. Washington DC: National Academy Press; 2002.
Metadata
Title
Capsule Commentary on Lafata et al., Medication Adherence Does Not Explain Black-White Differences in Cardiometabolic Risk Factor Control among Insured Patients with Diabetes
Author
Ana M. Palacio, MD, MPH
Publication date
01-02-2016
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 2/2016
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-015-3510-4

Other articles of this Issue 2/2016

Journal of General Internal Medicine 2/2016 Go to the issue

Letter to the Editor

Re: Underuse and Overuse of Osteoporosis Screening in a Regional Health System: A Retrospective Cohort Study

Original Research

Unintentional Continuation of Medications Intended for Acute Illness After Hospital Discharge: A Population-Based Cohort Study

Perspective

Industry Support of Medical Research: Important Opportunity or Treacherous Pitfall?

Editorial

Training Future Physicians to Deliver Tobacco Cessation Treatment

Capsule Commentary

Capsule Commentary on Scales et al., Unintentional Continuation of Medications Intended for Acute Illness After Hospital Discharge: A Population-Based Cohort Study

Original Research

Medication Adherence Does Not Explain Black-White Differences in Cardiometabolic Risk Factor Control among Insured Patients with Diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits